Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arsenic trioxide - Teva Pharmaceutical Industries

Drug Profile

Arsenic trioxide - Teva Pharmaceutical Industries

Alternative Names: NSC-706363; Trisenox

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CTI BioPharma
  • Developer Leukemia SPORE; Northwestern University; Temple University; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelodysplastic syndromes; Liver cancer; Chronic myeloid leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase I/II Glioma
  • Discontinued Multiple myeloma

Most Recent Events

  • 06 Aug 2018 National Institutes of Health and Teva Pharmaceuticals terminates a phase I trial for Chronic myeloid leukaemia (second-line therapy or greater, combination thereapy) in USA (NCT01397734)
  • 08 May 2018 The National Institute for Health and Care Excellence in the UK recommended arsenic trioxide for Acute promyelocytic leukaemia
  • 15 Jan 2018 Registered for Acute promyelocytic leukaemia (Combination therapy, Newly diagnosed) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top